Table 5

Intention-to-Treat Analysis of Secondary Outcomes

OutcomeIntervention GroupControl GroupAdjusteda Odds Ratio or Mean Difference (95% CI)P Value
Drug-specific outcomes
Proton pump inhibitor, No. (%)
 Baseline53 (53.5)65 (67.7)
 Intervention completion23 (23.2)46 (47.4)0.30 (0.14–0.68).04
Duplicate, No. (%)
 Baseline19 (19.2)13 (13.5)
 Intervention completion11 (11.1)11 (11.3)0.83 (0.32–2.13).99
Long-term benzodiazepines,
 No. (%)
 Baseline14 (14.1)8 (8.1)
 Intervention completion9 (9.1)9 (9.1)1.31 (0.47–3.68).99
Patient-reported outcomes
WBQ-12 score: mean well-beingb
 Baseline24.324.4
 Intervention completion23.624.0–0.41 (−0.80 to 1.07).99
BMQ score: median necessity-concern differentialc
 Baseline7.05.8
 Intervention completion6.06.00.16 (−1.85 to 1.07).99
  • BMQ = Beliefs About Medicine Questionnaire; WBQ-12 = 12-item Well-Being Questionnaire.

  • Note: Figures are numbers (percentages) unless stated otherwise. The Bonferroni method was used to account for multiple comparisons.

  • a Adjusted for age, sex, baseline number of PIP drugs, baseline number of repeat medications, number of general practitioners, and practice location.

  • b Well-being score ranges from 0 to 36 (1–12 low, 13–24 medium, 25–36 high).

  • c Scale from −20 to 20, where positive scores indicate benefits outweigh risks.